Foghorn Therapeutics Inc. (FHTX) NASDAQ

3.64

-0.335(-8.43%)

Updated at June 02 12:43PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Adrian H. Gottschalk	President, Chief Executive Officer & Director	1.03M	1976
Karin Hellsvik	Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations	0	N/A
Anna Rivkin	Chief Business Officer	348,672	1975
Michael J. LaCascia	Chief Legal Officer	565,500	1965
Ryan D. Maynard	Chief Financial Officer	637,806	1969
Alfonso Quintas Cardama	Chief Medical Officer	714,360	1971
Steven F. Bellon	Chief Scientific Officer	730,200	1965
Jeffrey Sacher	Treasurer	0	1966
Carlos Costa	Chief People Officer	0	1973
Michael Garcia-Webb	VP, Program Executive & Chief of Staff Research	0	N/A
Saurabh Sewak	Vice President of Corporate Development	0	N/A
Gerald R. Crabtree	Founder & Member of Scientific Advisory Board	0	N/A

Name

Title

Pay

Year Born

Adrian H. Gottschalk

President, Chief Executive Officer & Director

1.03M

1976

Karin Hellsvik

Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations

N/A

Anna Rivkin

Chief Business Officer

348,672

1975

Michael J. LaCascia

Chief Legal Officer

565,500

1965

Ryan D. Maynard

Chief Financial Officer

637,806

1969

Alfonso Quintas Cardama

Chief Medical Officer

714,360

1971

Steven F. Bellon

Chief Scientific Officer

730,200

1965

Jeffrey Sacher

Treasurer

1966

Carlos Costa

Chief People Officer

1973

Michael Garcia-Webb

VP, Program Executive & Chief of Staff Research

N/A

Saurabh Sewak

Vice President of Corporate Development

N/A

Gerald R. Crabtree

Founder & Member of Scientific Advisory Board

N/A

Description

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.